StockWatch: Moderna Seeks to Reassure Investors on RFK Jr

MRNA reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 billion. Here are some of the major companies whose stocks moved on the week’s news. Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S.

“The size of our late-stage pipeline combined with the challenge of launching products means we must now focus on delivering these 10 products to patients, slow down the pace of new R&D investment, and build our commercial business,” said chief executive officer Stéphane Bancel. First, let’s consider all of the important points Moderna talked about during its annual R&D day — and why it’s making certain decisions. Lowering its R&D expenses and slashing certain programs will result in fewer products launched in the next few years. This is after — just last year — forecasting the launch of as many as 15 new products over the next five years. As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Charles Schwab Investment Management Inc. lifted its stake in Moderna by 4.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,132,777 shares of the company’s stock worth $142,533,000 after purchasing an additional 83,082 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Moderna by 11.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after buying an additional 167,596 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Moderna by 2.1% in the 2nd quarter.

Vaccine maker stocks fall on reports Trump plans to tap RFK Jr. to lead HHS

The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was inside bar trading strategy founded in 2010 and is headquartered in Cambridge, Massachusetts.

Centers for Disease Control and Prevention (CDC), for which Dave Weldon, MD, a physician and former Republican Congressman from Florida, will be nominated as director. The bad news is that Moderna will take longer than originally expected to get to the break-even point. Shareholders who have already been disappointed by declining sales in recent years won’t take this lightly. And if you haven’t yet invested in Moderna, you may not see the biotech as an exciting growth player at the moment.

Moderna (MRNA) shares surged Friday, a day after a senior executive made bullish comments at a healthcare conference about the vaccine maker’s pipeline and cash position. Moderna is projecting $4 billion in revenue this year, which factors in approval of its respiratory syncytial virus (RSV) vaccine, which the company anticipates should come within the first half of the year. The company is still working on a combination shot for COVID and the flu, which looks to still be part of its long-term strategy.

About MRNA

What is important for the future of the business, and for current and potential investors, is the pipeline of future products. During the luncheon, Bancel and Hoge “expressed strong confidence” in the comeback strategy they laid out for Moderna in September at its annual R&D Day. Moderna committed to stepping up the development of vaccines for cancer and rare diseases, while dialing back investment in infectious disease jabs.

© 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Moderna (MRNA) raised $499 million in an initial public offering on Friday, December 7th 2018.

Investing Groups

• “We expect to end the year with $9 billion in cash,” Talukdar said, according to a transcript provided by AlphaSense.
• But this isn’t a stock I’d buy today as there isn’t anything terribly exciting in its pipeline outside of its personalized cancer vaccine.
• If it is still relying on COVID revenue, that could be a bad sign, indicating that the company hasn’t come out with more promising products along the way.
• There’s no doubt that the success of the COVID-19 vaccine was proof that mRNA technology is a viable path to pursue for Moderna, which took a lot of the risk out of an investment in the company.
• Moderna is working in other areas as well, including respiratory vaccines, oncology therapeutics, and rare disease therapeutics.

Further down the road are therapeutics for cancer and other diseases that could be additional catalysts for growth. Over this year and 2025, Moderna expects to have more products come to market. In addition to the updated versions of the COVID metatrader 5 for mac vaccine, Moderna expects approval of a flu/COVID combination vaccine, as well as a vaccine for Respiratory Syncytial Virus (RSV). Beyond 2025, the company is projecting that several more products will come to market, pending the appropriate regulatory approvals. What followed was a wild ride in which Moderna burst into the public consciousness as it developed and began selling one of the COVID-19 vaccines, putting the company and its mRNA technology at the forefront of investors’ minds.

Discover which analysts rank highest on predicting the price target of MRNA. Discover which analysts rank highest for MRNA overall weighted by direction, price target, and price movement. While Moderna currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

But it will take years for sales from those products, assuming they obtain approval, to flow through to the business. Moderna is not the only company working on mRNA, but it is review mastering bitcoin: programming the open blockchain the company’s focus, and therefore it can put all its resources toward that technology. Moderna is working in other areas as well, including respiratory vaccines, oncology therapeutics, and rare disease therapeutics. Moderna has a lot of trials going on and may have a lot of potential sources of revenue in the future. But this isn’t a stock I’d buy today as there isn’t anything terribly exciting in its pipeline outside of its personalized cancer vaccine.